⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

June 3, 2024Open Access

Supplementary Figure S7 from A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma

James Brugarolas Gregory Obara Kathryn E. Beckermann Brian I. Rini Elaine T. Lam James Hamilton Thomas Schluep Min Yi So C. Wong Zhongping Lily Mao Érick Gamelin Nizar M. Tannir

View Full Paper

Ask AI

Bookmark

Share

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Abstract

Figure S7. Summary of Percent Change in Vascular Endothelial Growth Factor (pg/mL) by Visit

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Brugarolas et al. (2024) studied this question.

synapsesocial.com/papers/68e66839b6db6435875f3c63 https://doi.org/10.1158/1078-0432.25956233.v1

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S7 from A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma2024
2Supplementary Figure S5 from A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma2024
3Supplementary Figure S5 from A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma2024
4Supplementary Figure S6 from A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma2024
5Supplementary Figure S6 from A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma2024

Supplementary Figure S2 from A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma2024
Supplementary Figure S2 from A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma2024
Supplementary Figure S3 from A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma2024